Participant flow15

How many started, completed or left each group, period by period.

1 to 15 of 15

Period	Milestone	Group	Participants
Overall Study	STARTED	Placebo Plus Regadenoson	114
Overall Study	STARTED	Caffeine 200 mg Plus Regadenoson	116
Overall Study	STARTED	Caffeine 400 mg Plus Regadenoson	117
Overall Study	Safety Analysis Set	Placebo Plus Regadenoson	113
Overall Study	Safety Analysis Set	Caffeine 200 mg Plus Regadenoson	116
Overall Study	Safety Analysis Set	Caffeine 400 mg Plus Regadenoson	116
Overall Study	Completed Treatment	Placebo Plus Regadenoson	66
Overall Study	Completed Treatment	Caffeine 200 mg Plus Regadenoson	71
Overall Study	Completed Treatment	Caffeine 400 mg Plus Regadenoson	72
Overall Study	COMPLETED	Placebo Plus Regadenoson	66
Overall Study	COMPLETED	Caffeine 200 mg Plus Regadenoson	70
Overall Study	COMPLETED	Caffeine 400 mg Plus Regadenoson	71
Overall Study	NOT COMPLETED	Placebo Plus Regadenoson	48
Overall Study	NOT COMPLETED	Caffeine 200 mg Plus Regadenoson	46
Overall Study	NOT COMPLETED	Caffeine 400 mg Plus Regadenoson	46

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT00826280/flow